One Plus One Wealth Management LLC Sells 675 Shares of Merck & Co., Inc. (NYSE:MRK)

One Plus One Wealth Management LLC decreased its position in shares of Merck & Co., Inc. (NYSE:MRK) by 18.5% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 2,980 shares of the company’s stock after selling 675 shares during the quarter. One Plus One Wealth Management LLC’s holdings in Merck & Co., Inc. were worth $338,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of the company. Capital World Investors increased its holdings in shares of Merck & Co., Inc. by 67.6% during the first quarter. Capital World Investors now owns 13,954,017 shares of the company’s stock worth $1,841,233,000 after buying an additional 5,627,923 shares in the last quarter. Raymond James & Associates raised its holdings in Merck & Co., Inc. by 1.2% in the 3rd quarter. Raymond James & Associates now owns 9,874,714 shares of the company’s stock valued at $1,121,372,000 after buying an additional 114,080 shares during the last quarter. Envestnet Asset Management Inc. boosted its position in Merck & Co., Inc. by 0.9% during the 2nd quarter. Envestnet Asset Management Inc. now owns 7,693,065 shares of the company’s stock worth $952,402,000 after buying an additional 64,996 shares during the period. Swedbank AB grew its holdings in Merck & Co., Inc. by 38.6% during the 3rd quarter. Swedbank AB now owns 7,530,111 shares of the company’s stock worth $855,119,000 after acquiring an additional 2,095,694 shares during the last quarter. Finally, Dimensional Fund Advisors LP lifted its stake in shares of Merck & Co., Inc. by 7.5% in the 2nd quarter. Dimensional Fund Advisors LP now owns 6,201,926 shares of the company’s stock valued at $767,965,000 after purchasing an additional 431,074 shares during the period. 76.07% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

MRK has been the subject of several recent analyst reports. Wolfe Research raised shares of Merck & Co., Inc. to a “strong-buy” rating in a research report on Wednesday, July 31st. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $155.00 target price on shares of Merck & Co., Inc. in a research report on Thursday, October 3rd. Wells Fargo & Company reduced their price objective on Merck & Co., Inc. from $125.00 to $110.00 and set an “equal weight” rating for the company in a research note on Friday, November 1st. Truist Financial cut their target price on Merck & Co., Inc. from $143.00 to $132.00 and set a “buy” rating on the stock in a report on Wednesday, October 9th. Finally, Evercore ISI raised shares of Merck & Co., Inc. to a “strong-buy” rating in a research note on Tuesday, July 30th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating, ten have issued a buy rating and four have issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $129.93.

Merck & Co., Inc. Stock Down 0.2 %

Shares of NYSE:MRK opened at $101.65 on Wednesday. The firm has a fifty day moving average of $111.71 and a 200 day moving average of $120.47. The firm has a market capitalization of $257.46 billion, a PE ratio of 21.31, a price-to-earnings-growth ratio of 1.46 and a beta of 0.40. Merck & Co., Inc. has a 52-week low of $98.60 and a 52-week high of $134.63. The company has a debt-to-equity ratio of 0.80, a quick ratio of 1.22 and a current ratio of 1.47.

Merck & Co., Inc. (NYSE:MRK) last announced its quarterly earnings data on Thursday, October 31st. The company reported $1.57 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.50 by $0.07. The firm had revenue of $16.66 billion for the quarter, compared to analysts’ expectations of $16.47 billion. Merck & Co., Inc. had a return on equity of 37.32% and a net margin of 19.23%. The company’s revenue for the quarter was up 4.4% compared to the same quarter last year. During the same period last year, the firm earned $2.13 earnings per share. As a group, research analysts anticipate that Merck & Co., Inc. will post 7.75 EPS for the current fiscal year.

About Merck & Co., Inc.

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names.